kulke m
Harvard University
H-index: 86
North America-United States
Top articles of kulke m
Title | Journal | Author(s) | Publication Date |
|---|---|---|---|
Corrigendum to" Sex differences on multikinase inhibitors toxicity in patients with advanced gastroenteropancreatic neuroendocrine tumours"[Eur J Cancer 188 (2023) 39-48] | European journal of cancer (Oxford, England: 1990) | Jorge Hernando Maria Roca-Herrera Alejandro García-Álvarez Eric Raymond Philippe Ruszniewski | 2024/4/11 |
Real-World comprehensive genomic profiling data for diagnostic clarity in pulmonary Large-Cell neuroendocrine carcinoma | Lung Cancer | Laura Burns Hanna Tukachinsky Kira Raskina Richard SP Huang Alexa B Schrock | 2024/2/1 |
Amanitin conjugates | 2023/2/28 | ||
PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer | Antonino Glaviano Aaron SC Foo Hiu Y Lam Kenneth CH Yap William Jacot | 2023/8/18 | |
PSMA-targeting amanitin conjugates | 2023/2/21 | ||
Method for synthesizing amanitins | 2023/7/18 | ||
Metastatic gastroenteropancreatic neuroendocrine tumors: local options to control tumor growth and symptoms of hormone hypersecretion | Post TW, Goldberg RM, Jaffe T et al | Jennifer Ang Chan Matthew Kulke Thomas E Clancy Tracy Jaffe | 2023 |
Sex differences on multikinase inhibitors toxicity in patients with advanced gastroenteropancreatic neuroendocrine tumours | European Journal of Cancer | Jorge Hernando Maria Roca-Herrera Alejandro García-Álvarez Eric Raymond Philippe Ruszniewski | 2023/7/1 |
Association of immune-related adverse events and improved treatment outcomes across race/ethnicity in a diverse patient population. | Chinmay Jani Amr Radwan Omar Al Omari Mohini Patel Laura Burns | 2023/6/1 | |
LBA53 Alliance A021602: Phase III, double-blinded study of cabozantinib versus placebo for advanced neuroendocrine tumors (NET) after progression on prior therapy (CABINET) | Annals of Oncology | J Chan S Geyer FS Ou M Knopp S Behr | 2023/10/1 |
Implementation of a housing insecurity screening tool in patients with lung cancer. | Laura Burns Sara Young Hyerim Jang Chinmay Jani Amr El Saman Radwan | 2023/6/1 | |
Intertumoral lineage diversity and immunosuppressive transcriptional programs in well-differentiated gastroenteropancreatic neuroendocrine tumors | Science Advances | Samantha E Hoffman Todd W Dowrey Carlos Villacorta Martin Kevin Bi Breanna Titchen | 2023/9/27 |
A phase II study of ziv-aflibercept in patients with advanced extrapancreatic neuroendocrine tumors | Pancreas | Kimberly Perez Matthew H Kulke Nora K Horick Eileen Regan Christopher Graham | 2022/8/1 |
An open-label, multicenter, randomized phase II study of atezolizumab and bevacizumab with Y90 TARE in patients with unresectable hepatocellular carcinoma (HCC). | Aiwu Ruth He Filip Banovac Renuka V Iyer Michael Petroziello Daniel Brown | 2022/6/1 | |
Everolimus with or without bevacizumab in advanced pNET: CALGB 80701 (Alliance) | Endocrine-related cancer | Matthew H Kulke Fang-Shu Ou Donna Niedzwiecki Lucas Huebner Pamela Kunz | 2022/6/1 |
Long-term treatment with telotristat ethyl in patients with carcinoid syndrome symptoms: Results from the TELEPATH study | Neuroendocrinology | Dieter Hörsch Lowell Anthony David J Gross Juan W Valle Staffan Welin | 2022/5/3 |
Amanitin antibody conjugates | 2022/9/20 | ||
The safety and efficacy of PEN-221 somatostatin analog (SSA)-DM1 conjugate in patients (pts) with advanced GI mid-gut neuroendocrine tumor (NET): Phase 2 Results | Daniel M Halperin Melissa L Johnson Jennifer A Chan Lowell L Hart Natalie Cook | 2022 | |
SDHx mutations and temozolomide in malignant pheochromocytoma and paraganglioma | Endocrine-related cancer | Kimberly Perez Heather Jacene Jason L Hornick Chao Ma Nuno Vaz | 2022/9/1 |
Time to sustained improvement in bowel movement frequency with telotristat ethyl: analyses of phase III studies in carcinoid syndrome | Journal of gastrointestinal cancer | Joseph S Dillon Matthew H Kulke Dieter Hörsch Lowell B Anthony Richard RP Warner | 2021/3 |
